A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting that combination therapy ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding ...

BMC Clin Pharmacol. 2011;11(17):1-10. The fully human nature of panitumumab was expected to decrease the rate of immunogenicity compared with therapeutic antibodies containing nonhuman coding ...

irinotecan, and capecitabine) and 3 biologic agents (bevacizumab, cetuximab, and panitumumab) as clinical options. However, these agents each have a high degree of variation in toxicity and ...

Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab ... chemotherapy based on fluoropyrimidine, oxaliplatin and irinotecan. The approval is anchored in the outcomes of the Phase III CodeBreaK ...

Third-line treatment with panitumumab alone or irinotecan plus cetuximab is reserved to those patients with KRAS wild-type tumors previously untreated with the anti-EGFR antibody. Whenever the ...